Theriva Biologics, Inc. (TOVX)
NYSEAMERICAN: TOVX · Real-Time Price · USD
0.357
+0.004 (1.05%)
At close: Apr 28, 2026, 4:00 PM EDT
0.350
-0.007 (-2.01%)
Pre-market: Apr 29, 2026, 8:19 AM EDT

Theriva Biologics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Net Income
-23.74-25.65-18.35-19.69-14.27
Upgrade
Depreciation & Amortization
0.110.140.140.090.09
Upgrade
Loss (Gain) From Sale of Assets
0----
Upgrade
Asset Writedown & Restructuring Costs
-6.92---
Upgrade
Stock-Based Compensation
0.650.670.550.480.42
Upgrade
Other Operating Activities
9.370.26-3.640.850.17
Upgrade
Change in Accounts Payable
0.070.12-0.16-0.39-0.36
Upgrade
Change in Other Net Operating Assets
-3.130.62.47-0.421.07
Upgrade
Operating Cash Flow
-16.67-16.94-19-19.08-12.89
Upgrade
Capital Expenditures
-0.04-0-0.2-0.12-0.01
Upgrade
Cash Acquisitions
----3.86-
Upgrade
Investing Cash Flow
-0.04-0-0.2-4.4-0.01
Upgrade
Long-Term Debt Issued
1.51----
Upgrade
Long-Term Debt Repaid
-0.07-0.07-0.08-1.38-
Upgrade
Net Debt Issued (Repaid)
1.44-0.07-0.08-1.38-
Upgrade
Issuance of Common Stock
17.475.562.22-74
Upgrade
Repurchase of Common Stock
----0.29-
Upgrade
Other Financing Activities
-0.71--1.52-3-
Upgrade
Financing Cash Flow
18.195.50.63-1.9374
Upgrade
Foreign Exchange Rate Adjustments
-0.09-0.13-0.03-0.03-
Upgrade
Net Cash Flow
1.4-11.57-18.61-25.4461.1
Upgrade
Free Cash Flow
-16.7-16.94-19.2-19.2-12.9
Upgrade
Free Cash Flow Per Share
-1.38-12.56-29.80-31.31-26.47
Upgrade
Levered Free Cash Flow
-5.98-10.55-14.41-10.42-7.51
Upgrade
Unlevered Free Cash Flow
-5.98-10.55-14.41-10.42-7.51
Upgrade
Change in Working Capital
-3.060.732.31-0.810.71
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.